Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14140168 | 1.00 | KMT2A (0.39) | KMT2ACA2MEN1PARP3SMN1; SMN2 | |
| SCHEMBL29294925 | 1.00 | KMT2A (0.39) | KMT2ACA2MEN1PARP3SMN1; SMN2 | |
| SCHEMBL14139801 | 1.00 | KMT2A (0.39) | KMT2ACA2MEN1PARP3SMN1; SMN2 | |
| SCHEMBL1501790 | 0.78 | MEN1 (0.44) | KMT2AMEN1SMN1; SMN2BRD4ALDH1A1 | |
| SCHEMBL21121204 | 0.77 | SMN1; SMN2 (0.45) | KMT2AMEN1SMN1; SMN2BRD4DDB1 | |
| SCHEMBL21121203 | 0.77 | SMN1; SMN2 (0.45) | KMT2AMEN1SMN1; SMN2BRD4DDB1 | |
| SCHEMBL22570414 | 0.77 | SMN1; SMN2 (0.45) | KMT2AMEN1SMN1; SMN2BRD4DDB1 | |
| SCHEMBL21121178 | 0.77 | SMN1; SMN2 (0.45) | KMT2AMEN1SMN1; SMN2BRD4DDB1 | |
| SCHEMBL2949431 | 0.77 | MAOB (0.42) | KMT2ACA2MEN1SMN1; SMN2BRD4 | |
| SCHEMBL20228733 | 0.77 | SMN1; SMN2 (0.45) | KMT2AMEN1SMN1; SMN2BRD4DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-06-05 | — | — | US | disclosed |
| EP-3548484-B1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2025-04-30 | — | — | EP | disclosed |
| CN-119613408-A | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4486743-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-01-08 | — | — | EP | disclosed |
| CN-110914271-B | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118765280-A | RIP1 modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240300974-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4397309-A2 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| WO-2019012063-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019012063-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2019-01-17 | — | — | WO | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018109097-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109097-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018100070-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018100070-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-07 | — | — | WO | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK3 | KMT2A 4318/4885CA2 4573/4885MEN1 3635/4885 |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | CYP4B1, CYP1B1, AADAC | KMT2A 1607/4885CA2 2291/4885MEN1 692/4885 |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | KMT2A 2986/4885CA2 3799/4885MEN1 2596/4885 |
| US-20240300974-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | KMT2A 1762/4885CA2 2835/4885MEN1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.